SAN DIEGO, April 24, 2018 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a
clinical-stage biopharmaceutical company committed to developing
and commercializing innovative products to address unmet needs in
women's sexual and reproductive health, announced today the launch
of an underwritten public offering of $40.0
million of its common stock. All of the shares in the
offering are to be sold by Evofem. As part of the offering, Evofem
expects to grant the underwriters a 30-day option to purchase up to
an additional $6.0 million of its
common stock offered in the public offering at the public offering
price, less the underwriting discount and commissions. The offering
is subject to market and other conditions and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
RBC Capital Markets LLC and Cantor Fitzgerald & Co. are
acting as joint book-running managers for the offering. Oppenheimer
& Co. Inc. is acting as lead manager, and Roth Capital
Partners, LLC, is acting as co-manager.
A registration statement on Form S-1 relating to the public
offering of the shares of common stock described above has been
filed with the Securities and Exchange Commission ("SEC"), but has
not yet become effective. The shares of common stock may not be
sold nor may offers be accepted prior to the time the registration
statement on Form S-1 becomes effective. This offering is being
made only by means of a prospectus. Evofem's SEC filings are
available to the public from the SEC's website at www.sec.gov.
Copies of the preliminary prospectus and final prospectus relating
to the offering may also be obtained, when available, by contacting
RBC Capital Markets LLC, Attention: Equity Syndicate, 200 Vesey
Street, 8th Floor, New York, NY
10281-8098 or by telephone at (877) 822-4089 or by email at
equityprospectus@rbccm.com or Cantor Fitzgerald & Co.,
Attention: Capital Markets, 499 Park Avenue, 6th Floor New York, New York 10022 or by email at
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation, or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is a clinical-stage biopharmaceutical company
committed to developing and commercializing innovative products to
address unmet needs in women's sexual and reproductive health.
Evofem is leveraging its proprietary Multi-purpose Prevention
Technology vaginal gel to develop product candidates for multiple
indications, including contraception, the prevention of urogenital
transmission of chlamydia and gonorrhea in women, and recurrent
bacterial vaginosis.
Forward-Looking Statements
Statements in this press
release about Evofem's future expectations, plans and prospects,
including as to the expected terms of the offering, as well as any
other statements regarding matters that are not historical facts,
may constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements
are often characterized by terminology such as "believes," "hopes,"
"may," "anticipates," "should," "intends," "plans," "will,"
"expects," "estimates," "projects," "positioned," "strategy" and
similar expressions and are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements are not guarantees of future performance and are subject
to risks and uncertainties, many of which are outside of the
Company's control. Important factors that could cause actual
results, developments and business decisions to differ materially
from forward-looking statements are described in the sections
titled "Risk Factors" in the Company's filings with the SEC,
including its most recent Annual Report on Form 10-K and Amendment
No. 1 to Registration Statement on Form S-1 filed with the SEC on
February 26, 2018 and April 24, 2018, respectively, and include but are
not limited to the following: risks and uncertainties associated
with market conditions; the Company's ability to satisfy customary
closing conditions related to the offering; the volatility of the
trading price of the Company's common stock, and the concentration
of power in its stock ownership. Forward-looking statements in this
press release are made as of the date of this press release, and
the Company undertakes no duty to update or revise any such
statements, whether as a result of new information, future events
or otherwise. These forward-looking statements should not be relied
upon as representing the Company's views as of any date subsequent
to the date hereof.
Evofem Biosciences' Contact
Amy Raskopf
Investor Relations
araskopf@evofem.com
858-550-1900 x167
View original content with
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-announces-proposed-public-offering-of-common-stock-300635018.html
SOURCE Evofem Biosciences, Inc.